- cafead   Jan 15, 2020 at 11:22: PM
via Sales of Clovis Oncology's (NASDAQ: CLVS) Rubraca could get a big lift just in time for summer. Today, the company told investors a supplemental application that could expand the addressable patient population of its lead drug will get a speedy review.
article source
article source